Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

November 13, 2024

Statins Are Cost-effective in the Elderly

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

June 05, 2024

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

September 13, 2023

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

News Conference News ESC 2021

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

Michael O'Riordan

August 29, 2021

Despite COVID-19 Heart Disease Remains Top US Killer AHA (1).jpeg

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

March 28, 2020

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

CVD Prevention and Control Remains a Challenge in India

News Daily News

CVD Prevention and Control Remains a Challenge in India

June 26, 2018

Alirocumab Price Slashed in Deal With Express Scripts

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

March 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.